Extensively Drug-Resistant Myroides odoratus in Critically Ill Patients: A Case Series and Literature Review

Table 2

Review of published antimicrobial susceptibility results for Myroides spp.

Myroides spp.	# Of isolates	#S	% S	Citation
Amikacin	161	1	<1	4–7, 9, 10, 17, 21–34, 36, 40, 41, this report
Amoxicillin or ampicillin	83	28	33.7	13, 17, 28, 32, 35, 36, 41
Amoxicillin/clavulanate	13	4	30.8	4, 10, 13, 28, 32, 36
Aztreonam	156	1	<1	4–6, 10, 13, 17, 21, 22, 25, 26, 28, 30–33, 35, 36, 40, 41, this report
Cefepime	129	1	<1	4–7, 10, 13, 17, 21–23, 25, 26, 28, 30–36, 41, this report
Cefoperazone	43	0	0.0	40, 41
Cefoperazone/sulbactam	14	1	7.1	5, 36, 41
Cefotaxime	13	0	0.0	10, 13, 28, 30, 32, 33
Cefoxitin	10	0	0.0	13, 28, 32
Ceftazidime	159	0	0.0	4–7, 9, 10, 13, 17, 21, 22, 25, 28, 30–36, 38, 40, 41, this report
Ceftazidime/avibactam	2	0	0.0	24, this report
Ceftolozane/tazobactam	1	0	0.0	this report
Ceftriaxone	62	0	0.0	5, 7, 10, 22, 23, 26, 33, 40, 41, this report
Cefuroxime	4	0	0.0	10, 13, 32
Chloramphenicol	21	1	4.8	10, 20, 28, 41
Ciprofloxacin	163	13	8.0	4–7, 9, 10, 17, 20–23, 25–31, 33–36, 38–41, this report
Colistin	91	0	0.0	17, 21, 25, 28, 31, 32, 36, 41
Ertapenem	4	0	0.0	38, this report
Fosfomycin	60	0	0.0	17, 24
Gentamicin	161	0	0.0	4–7, 9, 10, 17, 21–34, 36, 40, 41, this report
Imipenem	158	3	1.9	5, 6, 9, 10, 13, 17, 21–26, 28, 30, 31, 33–36, 38–41
Levofloxacin	102	20	19.6	4, 5, 9, 10, 17, 20, 22, 23, 25, 27, 30, 32, 33, 35, 36, this report
Meropenem	122	32	26.2	4–8, 11, 13, 17, 22, 24–26, 29–34, 36–38, 41, this report
Meropenem/vaborbactam	1	0	0.0	this report
Minocycline	19	19	100.0	31, 41, this report
Moxifloxacin	61	56	91.8	10, 17, this report
Piperacillin/tazobactam	124	17	13.7	4–7, 9, 10, 13, 17, 21–26, 29–33, 35, 36, 41, this report
Tetracycline	41	0	0.0	10, 26, 28, 33, 40
Tigecycline	69	54	78.3	17, 28, 32, this report
Tobramycin	58	1	1.7	4–6, 9, 21, 23, 24, 26–33, 40, this report
Trimethoprim/sulfamethoxazole	155	50	32.3	4–7, 9, 10, 17, 21–24, 28–33, 35, 36, 38, 40, 41, this report

When MICs were available, CLSI breakpoints for Enterobacterales were used for susceptibility interpretation. The cases in this report were considered 3 distinct isolates.